Predictive Oncology FY2022: Net loss $25.7M, revenue $1.5M, impairments total $10.6M

Axe Compute Inc.

Net loss of $25.7M on total revenue of $1.5M; diluted EPS -$0.35.
Revenue $1.51M vs $1.42M prior year; gross margin stable at 66%.
Recorded $7.23M goodwill impairment and $3.35M intangible impairment for zPREDICTA.
Cash and equivalents $22.1M at year end, down from $28.2M in 2021.
Operations expense up 41% to $3.8M; sales & marketing expense rose 75% to $1.36M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axe Compute Inc. reported the year ended December 31, 2022 results: revenue $1.5 million, net income net loss of $25.7 million, EPS $0.35.

Period: the year ended December 31, 2022
Revenue: $1.5 million
Net income: net loss of $25.7 million
EPS: $0.35
Result: reported results

Exact text from the filing

The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.